{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05782816",
            "orgStudyIdInfo": {
                "id": "22-0240"
            },
            "organization": {
                "fullName": "The University of Texas Medical Branch, Galveston",
                "class": "OTHER"
            },
            "briefTitle": "Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor",
            "officialTitle": "Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor: A Randomized Control Trial",
            "therapeuticArea": [
                "Other"
            ],
            "study": "low-dose-versus-high-dose-oxytocin-dosing-for-induction-and-augmentation-of-labor"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-04-17",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-02-21",
            "studyFirstSubmitQcDate": "2023-03-20",
            "studyFirstPostDateStruct": {
                "date": "2023-03-24",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-07",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "The University of Texas Medical Branch, Galveston",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to compare oxytocin infusion rates for induction and augmentation of labor in nulliparous women. The main question\\[s\\] it aims to answer are:\n\n* Does a high dose oxytocin infusion protocol affect length of induction to delivery interval?\n* Does a high dose oxytocin infusion protocol affect mode of delivery?\n* Does a high dose oxytocin infusion protocol affect maternal and neonatal outcomes?\n\nParticipants will be randomized to either low- or high-dose oxytocin groups:\n\n* The low dose group will receive an infusion to start at 2 milli-units/min and will be increased by 2 milli-units/min every 20 minutes. The maximum rate of infusion is 40 milli-units/min.\n* The high dose group will receive an infusion to start at 6 milli-units/min and will be increased by 6 milli-units/min every 20 minutes. Maximum rate of infusion is 40 milli-units/min."
        },
        "conditionsModule": {
            "conditions": [
                "Labor Long"
            ],
            "keywords": [
                "induction of labor",
                "augmentation of labor",
                "oxytocin",
                "pitocin",
                "high dose",
                "mode of delivery"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "whoMasked": [
                        "PARTICIPANT"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 170,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Low dose oxytocin",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "The low dose oxytocin group will receive a controlled infusion pump at a proximal port on the peripheral IV line. The infusion will start at 2 milli-units/min and will be increased by 2 milli-units/min every 20 minutes. Maximum rate of infusion is 40 milli-units/min. Oxytocin infusion rate is adjusted to maintain adequate uterine contractions.",
                    "interventionNames": [
                        "Drug: Oxytocin"
                    ]
                },
                {
                    "label": "High dose oxytocin",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "The high dose oxytocin group will receive a controlled infusion pump at a proximal port on the peripheral IV line. The infusion will start at 6 milli-units/min and will be increased by 6 milli-units/min every 20 minutes. Maximum rate of infusion is 40 milli-units/min. Oxytocin infusion rate is adjusted to maintain adequate uterine contractions.",
                    "interventionNames": [
                        "Drug: Oxytocin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Oxytocin",
                    "description": "Low dose oxytocin",
                    "armGroupLabels": [
                        "Low dose oxytocin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Oxytocin",
                    "description": "High dose oxytocin",
                    "armGroupLabels": [
                        "High dose oxytocin"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Time to delivery",
                    "description": "Induction to delivery time interval",
                    "timeFrame": "through study completion, expected to be 2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Mode of delivery",
                    "description": "Vaginal or cesarean delivery",
                    "timeFrame": "through study completion, expected to be 2 years"
                },
                {
                    "measure": "Rate of primary cesarean delivery",
                    "timeFrame": "through study completion, expected to be 2 years"
                },
                {
                    "measure": "Maximum dose of oxytocin infusion",
                    "timeFrame": "through study completion, expected to be 2 years"
                },
                {
                    "measure": "Number of participants with uterine tachysystole",
                    "description": "with and without fetal heart rate changes, need for cessation or decrease in oxytocin dosage",
                    "timeFrame": "through study completion, expected to be 2 years"
                },
                {
                    "measure": "Rate of postpartum hemorrhage",
                    "timeFrame": "through study completion, expected to be 2 years"
                },
                {
                    "measure": "Rate of placental abruption",
                    "timeFrame": "through study completion, expected to be 2 years"
                },
                {
                    "measure": "Number of participants with nausea/vomiting requiring antiemetics and diarrhea",
                    "description": "Maternal side effects",
                    "timeFrame": "through study completion, expected to be 2 years"
                },
                {
                    "measure": "Rate of maternal infection (endometritis, chorioamnionitis)",
                    "description": "Maternal side effects",
                    "timeFrame": "through study completion, expected to be 2 years"
                },
                {
                    "measure": "Rate of serious maternal morbidity and mortality",
                    "description": "uterine rupture, admission to ICU, septicemia",
                    "timeFrame": "through study completion, expected to be 2 years"
                },
                {
                    "measure": "Number of neonates with one or more of: perinatal death, severe respiratory distress requiring ventilation, neonatal encephalopathy, neonatal seizure, neonatal sepsis, 5-minute APGAR score <7, umbilical artery acidemia, neonatal ICU admission",
                    "timeFrame": "through study completion, expected to be 2 years"
                },
                {
                    "measure": "Rate of neonatal infection",
                    "timeFrame": "through study completion, expected to be 2 years"
                },
                {
                    "measure": "Rate of neonates with 5 min APGAR score <7",
                    "timeFrame": "through study completion, expected to be 2 years"
                },
                {
                    "measure": "Rate of umbilical artery acidemia",
                    "timeFrame": "through study completion, expected to be 2 years"
                },
                {
                    "measure": "Rate of NICU admission",
                    "timeFrame": "through study completion, expected to be 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Women aged 18-50 years old\n* Singleton gestation\n* Nulliparous\n* Vertex presentation\n* Gestational age greater than or equal to 37 weeks\n* No prior uterine surgery\n* Presents for elective or medically indicated induction of labor\n* Need for augmentation of labor with oxytocin\n\nExclusion Criteria:\n\n* Previous cervical ripening using non-mechanical methods\n* Patient unable or unwilling to provide verbal consent\n* Contraindications to vaginal delivery\n* Fetal demise or life-limiting anomaly\n* Allergy to oxytocin\n* Non-reassuring fetal heart tracing prior to inclusion\n* Maternal pulmonary edema prior to inclusion\n* Fetal growth restriction",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "genderBased": true,
            "minimumAge": "18 Years",
            "maximumAge": "50 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Amanda Wang, MD",
                    "role": "CONTACT",
                    "phone": "409-772-2891",
                    "email": "ammwang@utmb.edu"
                },
                {
                    "name": "Luis Pacheco, MD",
                    "role": "CONTACT",
                    "phone": "409-772-2891",
                    "email": "ldpachec@utmb.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Amanda Wang, MD",
                    "affiliation": "University of Texas",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Texas Medical Branch",
                    "status": "RECRUITING",
                    "city": "Galveston",
                    "state": "Texas",
                    "zip": "77555",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amanda Wang, MD",
                            "role": "CONTACT",
                            "phone": "409-772-2891",
                            "email": "ammwang@utmb.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.30135,
                        "lon": -94.7977
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010121",
                    "term": "Oxytocin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010120",
                    "term": "Oxytocics"
                },
                {
                    "id": "D000012102",
                    "term": "Reproductive Control Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13041",
                    "name": "Oxytocin",
                    "asFound": "State",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4854",
                    "name": "Benzocaine",
                    "relevance": "LOW"
                },
                {
                    "id": "T433",
                    "name": "Tannic Acid",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Repr",
                    "name": "Reproductive Control Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "Ot",
                    "name": "Other Dietary Supplements"
                }
            ]
        }
    },
    "hasResults": false
}